Q3 2021 ase 2 initiation hase 1 results Q4 2021 SUSTAIN FORTE EU decision Phase 2 initiation Phase 3 initiation ase 3 initiation e 1b/2a initiation EU decision Phase 3 results in GHD 2 Phase 1/2 results Phase 3 initiation 3 ase 2 initiation se 2 results (F4) ase 2b initiation ase 3 initiation al read-out expected around the turn of the year ide; HFpEF: Heart Failure with preserved Ejection Fraction; stage F4 in NASH: Compensated Cirrhosis Novo Nordisk ® Clinical milestones 1 Regulatory milestones 1 H1 2022 SUSTAIN FORTE US decision Phase 1 results Phase 3a results Phase 1 results Phase 3 initiation Phase 1 results Phase 3a results
Download PDF file